This product has consistently shown efficacy in supporting respiratory health relating to a range of conditions from the common cold to cystic fibrosis. A peer-reviewed paper was published in the Journal of the American Nutraceutical Association.
This first generation of this product candidate has undergone three successful FDA-authorized clinical trials for cystic fibrosis, chronic bronchitis, and COPD. Noting that the chronically inflamed lungs of the COPD patient are compromised by progressive scarring which not only decreases flexibility of the lungs so as to make them less able to expand, but also allows for entrapment of particles that cause inflammation and microorganisms that cause pneumonia, the status of patients was improved by adding our scar formulation to the initial respiratory product.
Significant work has been performed to determine the mechanism of action this product using gene micro array systems. We now know which genes are up- and down-regulated by this agent and have initiated conformational studies by polymerase chain reaction (PCR) to ensure in vitro activities are also reflected in vivo.
Patients in all three FDA trials experienced improved respiratory capacity. In the COPD trial, for example, after 90 days patients realized statistically significant beneficial results as measured by the six-minute walk.
Laboratory and lab animal work continues with respiratory and scarring agents individually as well as collectively for the COPD formulation